Enveric Corrects Proposed Reverse Split Range to 1-for-5 to 1-for-15 in Proxy
ENVB has more than doubled off its 52-week low of $1.71.
Summary
Enveric Biosciences has filed a supplemental proxy statement to correct a typographical error regarding its proposed reverse stock split. The company clarified that the proposed range for the reverse split is 1-for-5 to 1-for-15, not 1-for-50 as previously stated. This correction provides crucial details for a significant corporate governance event, as reverse stock splits are often implemented by companies with low stock prices to avoid delisting and improve institutional appeal. Given the company's recent 10-K filing indicating substantial doubt about its ability to continue as a going concern and its reliance on dilutive capital raises, the specific terms of this reverse split are highly material to investors. The annual meeting to vote on this and other proposals remains scheduled for May 28.
At the time of this announcement, ENVB was trading at $3.82 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.8M. The 52-week trading range was $1.71 to $17.84. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Wiseek News.